ADELPHI, Md. - An FDA panel Thursday said the benefits of Theratechnologies Inc.'s Egrifta (tesamorelin acetate) in reducing excess abdominal fat in HIV-infected patients with lipodystrophy outweighed the drug's potential risks of diabetes and cancer. (BioWorld Today) Read More
